FOCAL POINTS (Courageous Discourse)

FOCAL POINTS (Courageous Discourse)

Statin Intolerance, a Clinical Phenomenon

Growing and popular clinical challenge is worth reviewing

Peter A. McCullough, MD, MPH's avatar
Peter A. McCullough, MD, MPH
Oct 28, 2025
∙ Paid
38
14
9
Share
Upgrade to paid to play voiceover

By Peter A. McCullough, MD, MPH

Nearly all my patients believe they are statin-intolerant even before taking their first dose! Popular figures in the health freedom movement have spoken out against these commonly used generic drugs which are over-the-counter in many countries. They are used to lower total and LDL-cholesterol and through that mechanism reduce the risks of atherosclerotic heart disease. I used Alter AI to develop this update on the popular problem of statin intolerance.

Statin-associated muscle symptoms (SAMS) - NPS MedicineWise

Introduction

Statins (3‑hydroxy‑3‑methyl‑glutaryl‑coenzyme A reductase inhibitors) are first‑line agents for the prevention of atherosclerotic cardiovascular disease (ASCVD). They reduce LDL‑cholesterol (LDL‑C) by 25–55 % and lower cardiovascular morbidity and mortality ¹. Despite robust efficacy, patient adherence is limited by adverse effects collectively termed statin intolerance—a growing clinical challenge that impairs therapy effectiveness and complicates secondary prevention ². Understanding its true prevalence, underlying biology, and management strategies is essential for rational lipid therapy.

Keep reading with a 7-day free trial

Subscribe to FOCAL POINTS (Courageous Discourse) to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Peter McCullough MD MPH
Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture